Current issues in clinical research and the development of new pharmaceuticals

Accountability in Research

Volumn 8, Issue 4, 2001, Pages 283-291

  Goldhammer, Alan ^a  

^a Pharmaceutical Research and Manufacturers of America   (United States)

Author keywords

Declaration of Helsinki; Drug development; Informed consent; Institutional review boards

Indexed keywords

PLACEBO;

ADVISORY COMMITTEE; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; CONFLICT OF INTEREST; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUSTRY; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; HUMAN EXPERIMENT; INFORMED CONSENT; LEGAL APPROACH; LEGAL ASPECT; MULTICENTER STUDY; NATIONAL BIOETHICS ADVISORY COMMISSION; ORGANIZATION AND MANAGEMENT; PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA); PROFESSIONAL STANDARD; STANDARD; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; LEGAL APPROACH; NATIONAL BIOETHICS ADVISORY COMMISSION; PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA);

ADVISORY COMMITTEES; CLINICAL TRIALS; CONFLICT OF INTEREST; CONTROLLED CLINICAL TRIALS; DRUG INDUSTRY; ETHICS COMMITTEES, RESEARCH; GOVERNMENT REGULATION; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; INVESTIGATIONAL NEW DRUG APPLICATION; MULTICENTER STUDIES; PLACEBOS; RESEARCH SUPPORT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0035552703     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989620108573981     Document Type: Review

References (22)

1. Boyd, E. A., and Bero, L. A. (2000) Assessing faculty financial relationships with industry. Journal of the American Medical Association 284:2209-2214.
2. CenterWatch, (2000) Grants from NIH and Industry for U.S. Clinical Trials to Exceed $4 Billion. Press release, 7 November.
3. Cho, M. K., Shohara, R., Schissel, A., and Rennie, D. (2000), Policies on faculty conflicts of interest at U.S. universities. Journal of the American Medical Association 284:2203-2208.
4. DeAngelis, C. D. (2000). Conflict of interest and the public trust. Journal of the American Medical Association 284:2237-2238.
5. Drazen, J. M., and Koski, G. (2000). To protect those who serve. New England Journal of Medicine 343:1643-1645.
6. Food and Drug Administration. Provisions for Good Clinical Practices. Available from: http://www.access.gpo.gov/nara/cfr/index.html; INTERNET.
7. International Conference on Harmonization (ICH) E6. Available from: http://www.fda.gov/cder/guidance/959fnl.pdf; INTERNET.
8. Kassirer, J. P. (2000). Financial indigestion. Journal of the American Medical Association 284:2156-2157.
9. Korn, D. (2000). Conflicts of interest in biomedical research, Journal of the American Medical Association 284:2234-2236.
10. Lo, B., Wolf, L. E., and Berkeley, A. (2000). Conflict of interest policies for investigators in clinical trials. The New England Journal of Medicine, 343:1616-1620.
11. Martin, J. B. and Kasper, D. L. (2000). In whose best interest? Breaching the academicindustrial wall. New England Journal of Medicine 343:1646-1648.
12. McCrary, S. V., Anderson, C. B., Jakovljevic, J., Khan, T., McCullough, L. B., Wray, N. P., and Brody, B. A. (2000). A national survey of policies on disclosure of conflicts of interest in biomedical research. New England Journal of Medicine 343:1621-1626.
13. National Bioethics Advisory Commission (NBAC). (2000). Ethical and policy issues in international research. Available from: http://bioethics.gov/toc_pdf.html; INTERNET.
14. Riis, P. (2000) Perspectives on the fifth revision of the Declaration of Helsinki. Journal of the American Medical Association 284:3045-3046.
15. Schmidt, M. J. (2001). Patient safety in clinical research: Accountability and actions in the pharmaceutical industry. Manuscript submitted for publication.
16. Shalala, D. (2000). Protecting research subjects-What must be done. New England Journal of Medicine 343:808-810.
17. Temple, R., and Ellenberg, S. (2000a). Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 133:455-463.
18. Temple, R., and Ellenberg, S. (2000b). Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases. Annals of Internal Medicine 133:464-470.
19. U.S. Regulatory Reporter. (2000). November 4-7.
20. Vastag, B. (2000). Helsinki discord? A controversial declaration. Journal of the American Medical Association 284:2983-2985.
21. Wechsler, J. (2000). Clinical trial controversies draw scrutiny. Applied Clinical Trials 28-31.
22. World Medical Association (2000). Declaration of Helsinki-Ethical principles for medical research involving human subjects. Journal of the American Medical Association 284:3043-3045.